New triple therapy shows promise for resistant cancers
NCT ID NCT05383482
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the combo could shrink tumors. Results are preliminary, and more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Afuresertib (a targeted drug), sintilimab (an immunotherapy), and chemotherapy (nab-paclitaxel or docetaxel)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with certain cancers that have stopped responding to standard immunotherapy.
- What could go wrong
- This is an early-phase trial with only 22 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Chongqing Cancer Hospital
Chongqing, Chengdu, China
-
Jilin Cancer Hospital
Changchun, Jilin, China
-
West China Second University Hosital, Sichuan University
Chengdu, Sichuan, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a pill keep lung cancer from returning after surgery?
- Can an antiviral make radiation more effective against cervical cancer?